Boston Scientific (BSX) Financials

Boston Scientific logo
$42.25 -0.74 (-1.73%)
As of 03:34 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Boston Scientific

Annual Income Statements for Boston Scientific

This table shows Boston Scientific's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-239 347 104 1,671 4,700 -115 985 642 1,570 1,853 2,898
Consolidated Net Income / (Loss)
-239 347 104 1,671 4,700 -82 1,041 698 1,592 1,846 2,892
Net Income / (Loss) Continuing Operations
-239 347 105 1,671 4,700 -81 1,040 698 1,592 1,846 2,892
Total Pre-Tax Income
-650 177 933 1,422 687 -79 1,076 1,141 1,985 2,282 3,385
Total Operating Income
-283 447 1,285 1,506 1,518 -80 1,199 1,649 2,343 2,603 3,613
Total Gross Profit
5,304 5,962 6,455 7,011 7,620 6,448 8,177 8,727 9,896 11,490 13,854
Total Revenue
7,477 8,386 9,048 9,823 10,735 9,913 11,888 12,682 14,240 16,747 20,074
Operating Revenue
7,477 8,386 9,048 9,823 10,735 9,913 11,888 12,682 14,240 16,747 20,074
Total Cost of Revenue
2,173 2,424 2,593 2,813 3,116 3,465 3,711 3,956 4,345 5,257 6,221
Operating Cost of Revenue
2,173 2,424 2,593 2,813 3,116 3,465 3,711 3,956 4,345 5,257 6,221
Total Operating Expenses
5,587 5,515 5,170 5,504 6,102 6,528 6,978 7,079 7,553 8,887 10,241
Selling, General & Admin Expense
2,873 3,099 3,294 3,569 3,941 3,787 4,359 4,520 5,190 5,984 6,887
Research & Development Expense
876 920 997 1,113 1,174 1,143 1,204 1,323 1,414 1,615 2,052
Amortization Expense
495 545 565 599 699 789 741 803 828 856 897
Other Operating Expenses / (Income)
70 79 68 70 65 45 -29 69 46 33 46
Impairment Charge
19 11 4.00 35 105 533 370 132 58 386 46
Restructuring Charge
26 28 37 36 38 52 40 24 69 16 101
Other Special Charges / (Income)
1,228 833 205 82 80 178 294 208 -53 -5.00 212
Total Other Income / (Expense), net
-367 -270 -353 -85 -831 1.00 -123 -508 -358 -321 -228
Interest Expense
284 233 229 241 473 361 341 470 265 305 349
Other Income / (Expense), net
-83 -37 -124 156 -358 362 218 -38 -93 -16 121
Income Tax Expense
-411 -170 828 -249 -4,013 2.00 36 443 393 436 493
Preferred Stock Dividends Declared
- - - 0.00 0.00 33 55 55 23 0.00 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest
- - - - - - 0.00 0.00 -1.00 -8.00 -6.00
Basic Earnings per Share
($0.18) $0.26 $0.08 $1.21 $3.38 ($0.08) $0.69 $0.45 $1.08 $1.26 $1.96
Weighted Average Basic Shares Outstanding
1.34B 1.36B 1.37B 1.38B 1.39B 1.42B 1.42B 1.43B 1.45B 1.47B 1.48B
Diluted Earnings per Share
($0.18) $0.25 $0.08 $1.19 $3.33 ($0.08) $0.69 $0.45 $1.07 $1.25 $1.94
Weighted Average Diluted Shares Outstanding
1.34B 1.38B 1.39B 1.40B 1.41B 1.42B 1.43B 1.44B 1.46B 1.49B 1.49B
Weighted Average Basic & Diluted Shares Outstanding
1.33B 1.33B 1.37B 1.38B 1.40B 1.42B 1.43B 1.43B 1.47B 1.48B 1.48B

Quarterly Income Statements for Boston Scientific

This table shows Boston Scientific's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
495 324 469 565 674 797 755 672 1,341 907 582
Consolidated Net Income / (Loss)
493 322 468 563 672 795 755 670 1,339 905 580
Net Income / (Loss) Continuing Operations
493 322 469 562 672 795 756 669 1,338 905 580
Total Pre-Tax Income
608 420 669 585 805 941 939 700 1,162 1,060 733
Total Operating Income
675 520 733 675 921 819 1,048 825 1,101 1,178 828
Total Gross Profit
2,648 2,850 2,897 3,095 3,210 3,424 3,542 3,678 3,614 3,848 3,428
Total Revenue
3,856 4,120 4,209 4,562 4,663 5,061 5,065 5,285 5,203 5,442 5,138
Operating Revenue
3,856 4,120 4,209 4,562 4,663 5,061 5,065 5,285 5,203 5,442 5,138
Total Cost of Revenue
1,209 1,270 1,312 1,466 1,453 1,637 1,523 1,608 1,590 1,594 1,710
Operating Cost of Revenue
1,209 1,270 1,312 1,466 1,453 1,637 1,523 1,608 1,590 1,594 1,710
Total Operating Expenses
1,973 2,330 2,164 2,420 2,288 2,605 2,494 2,854 2,513 2,670 2,600
Selling, General & Admin Expense
1,364 1,446 1,562 1,612 1,597 1,716 1,741 1,833 1,781 1,803 1,683
Research & Development Expense
366 383 407 459 443 526 514 569 516 554 520
Amortization Expense
214 213 205 224 219 225 225 228 232 233 234
Other Operating Expenses / (Income)
10 9.00 5.00 9.00 14 14 12 6.00 12 12 12
Impairment Charge
- 276 0.00 - - 46 0.00 - - 0.00 39
Restructuring Charge
3.00 1.00 8.00 4.00 10 83 -8.00 16 3.00 8.00 63
Other Special Charges / (Income)
17 2.00 -23 -1.00 5.00 -5.00 11 201 -30 60 49
Total Other Income / (Expense), net
-67 -100 -65 -73 -116 123 -110 -125 61 -119 -96
Interest Expense
69 77 79 80 82 90 87 90 90 96 100
Other Income / (Expense), net
2.00 -23 14 - -34 213 -23 -35 151 -23 4.00
Income Tax Expense
115 98 200 23 133 146 183 31 -176 155 153
Net Income / (Loss) Attributable to Noncontrolling Interest
-1.00 -2.00 0.00 -7.00 -2.00 -2.00 0.00 -2.00 -2.00 -2.00 -2.00
Basic Earnings per Share
$0.34 $0.22 $0.32 $0.38 $0.46 $0.54 $0.51 $0.45 $0.90 $0.62 $0.40
Weighted Average Basic Shares Outstanding
1.47B 1.47B 1.47B 1.47B 1.48B 1.48B 1.48B 1.48B 1.48B 1.47B 1.45B
Diluted Earnings per Share
$0.33 $0.22 $0.32 $0.38 $0.45 $0.53 $0.51 $0.45 $0.90 $0.61 $0.40
Weighted Average Diluted Shares Outstanding
1.48B 1.48B 1.49B 1.49B 1.49B 1.49B 1.50B 1.49B 1.50B 1.47B 1.45B
Weighted Average Basic & Diluted Shares Outstanding
1.47B 1.47B 1.47B 1.48B 1.48B 1.48B 1.48B 1.48B 1.49B 1.45B 1.45B

Annual Cash Flow Statements for Boston Scientific

This table details how cash moves in and out of Boston Scientific's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-223 87 530 -187 -232 1,388 173 -1,042 -70 -450 1,541
Net Cash From Operating Activities
691 1,182 1,426 310 1,836 1,508 1,870 1,526 2,503 3,435 4,534
Net Cash From Continuing Operating Activities
691 1,182 1,426 311 1,838 1,508 1,871 1,527 2,505 3,434 4,534
Net Income / (Loss) Continuing Operations
-239 347 104 1,671 4,700 -82 1,041 698 1,592 1,846 2,892
Consolidated Net Income / (Loss)
-239 347 104 1,671 4,700 -82 1,041 698 1,592 1,846 2,892
Depreciation Expense
769 815 844 894 1,011 1,123 1,093 1,136 1,196 1,269 1,368
Amortization Expense
36 22 10 6.00 46 58 34 32 6.00 51 132
Non-Cash Adjustments To Reconcile Net Income
331 68 237 -91 713 432 -24 541 434 728 346
Changes in Operating Assets and Liabilities, net
-206 -70 231 -2,169 -4,632 -23 -273 -880 -723 -460 -204
Net Cash From Investing Activities
-2,186 -887 -1,010 -1,921 -5,041 -411 -1,596 -2,011 -2,574 -5,687 -2,640
Net Cash From Continuing Investing Activities
-2,186 -887 -1,010 -1,922 -5,042 -411 -1,596 -2,011 -2,574 -5,687 -2,639
Purchase of Property, Plant & Equipment
-247 -376 -319 -316 -461 -376 -554 -588 -711 -790 -876
Acquisitions
-1,734 -408 -560 -1,448 -4,382 -3.00 -2,258 -1,542 -1,811 -4,640 -1,593
Purchase of Investments
-266 -132 -131 -172 -348 -146 279 32 -89 -280 -254
Other Investing Activities, net
- - 0.00 0.00 52 87 82 70 37 23 84
Net Cash From Financing Activities
1,276 -206 110 1,432 2,973 293 -95 -548 5.00 1,814 -395
Net Cash From Continuing Financing Activities
1,277 -206 110 1,431 2,973 294 -95 -547 6.00 1,814 -395
Repayment of Debt
-1,715 -820 -3,216 -1,171 -5,135 -6,843 0.00 -3,435 -81 -318 -1,784
Issuance of Debt
3,100 630 3,339 2,576 7,929 5,844 0.00 3,270 0.00 2,145 1,558
Issuance of Common Equity
114 111 85 101 123 1,086 110 136 182 230 282
Other Financing Activities, net
-222 -127 -98 -75 56 -205 -150 -463 -95 -243 -451
Effect of Exchange Rate Changes
-4.00 -2.00 4.00 -8.00 - -2.00 -6.00 -9.00 -4.00 -11 42
Cash Interest Paid
283 233 235 262 449 359 338 450 259 250 319
Cash Income Taxes Paid
80 94 42 1,037 242 207 302 662 512 656 561

Quarterly Cash Flow Statements for Boston Scientific

This table details how cash moves in and out of Boston Scientific's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
1,441 565 -412 -2,044 314 -220 776 671 -504 -891 45
Net Cash From Operating Activities
164 813 1,002 1,456 541 1,286 1,343 1,364 348 1,474 1,048
Net Cash From Continuing Operating Activities
163 813 1,004 1,454 541 1,287 1,342 1,364 348 1,473 1,048
Net Income / (Loss) Continuing Operations
493 322 469 562 672 795 755 670 1,339 904 580
Consolidated Net Income / (Loss)
493 322 469 562 672 795 755 670 1,339 904 580
Depreciation Expense
304 311 306 348 325 336 342 365 351 355 361
Amortization Expense
0.00 - - 51 81 37 9.00 5.00 2.00 4.00 2.00
Non-Cash Adjustments To Reconcile Net Income
113 377 49 117 148 -144 193 149 -456 480 -186
Changes in Operating Assets and Liabilities, net
-747 -197 180 376 -685 263 43 175 -888 -270 291
Net Cash From Investing Activities
-285 -271 -1,427 -3,704 -500 -1,126 -502 -512 -591 -1,956 -437
Net Cash From Continuing Investing Activities
-285 -272 -1,426 -3,705 -500 -1,126 -503 -510 -591 -1,957 -436
Purchase of Property, Plant & Equipment
-179 -155 -179 -277 -187 -157 -181 -351 -177 -195 -180
Acquisitions
-47 -48 -1,127 -3,418 -239 -1,009 -256 -89 -523 -195 -212
Purchase of Investments
-66 -73 -125 -16 -77 -33 -70 -74 61 -1,791 -71
Sale and/or Maturity of Investments
- - - - - - - - - - 27
Net Cash From Financing Activities
1,569 24 7.00 214 233 -340 -104 -184 -260 -410 -569
Net Cash From Continuing Financing Activities
1,569 24 7.00 213 234 -340 -106 -183 -260 -409 -570
Repayment of Debt
-504 - - 187 -1,285 -309 -209 9.00 -256 1,667 -672
Issuance of Common Equity
80 26 96 28 115 32 115 20 81 5.00 95
Other Financing Activities, net
-152 -2.00 -111 -4.00 -154 -63 -12 -212 -85 -81 7.00

Annual Balance Sheets for Boston Scientific

This table presents Boston Scientific's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
18,133 18,096 19,042 20,999 30,565 30,777 32,229 32,469 35,136 39,395 43,673
Total Current Assets
3,471 3,239 3,822 4,003 4,699 6,694 6,317 5,760 6,514 6,920 8,794
Cash & Equivalents
319 196 188 146 217 1,734 1,925 928 865 414 1,965
Note & Lease Receivable
1,275 1,472 1,548 1,608 1,828 1,531 1,778 1,970 2,228 2,558 2,926
Inventories, net
1,016 955 1,078 1,166 1,579 1,351 1,610 1,867 2,484 2,810 2,943
Prepaid Expenses
365 541 942 921 880 751 799 731 621 831 660
Current Deferred & Refundable Income Taxes
496 75 66 161 195 194 205 264 315 307 299
Plant, Property, & Equipment, net
1,490 1,630 1,697 1,782 2,079 2,084 2,252 2,446 2,859 3,294 4,036
Total Noncurrent Assets
13,172 13,227 13,523 15,216 23,787 21,999 23,661 24,264 25,762 29,182 30,842
Long-Term Investments
- - - - - - - - - - 681
Goodwill
6,473 6,678 6,998 7,911 10,176 9,951 11,988 12,920 14,387 17,089 18,282
Intangible Assets
6,194 5,883 5,837 6,372 7,886 5,917 6,121 5,902 6,003 6,684 7,019
Noncurrent Deferred & Refundable Income Taxes
- - - 87 4,196 4,210 4,142 3,942 3,841 3,655 3,675
Other Noncurrent Operating Assets
505 666 688 846 1,529 1,921 1,410 1,500 1,531 1,754 1,185
Total Liabilities & Shareholders' Equity
18,133 18,096 19,042 20,999 30,565 30,777 32,229 32,469 35,136 39,395 43,673
Total Liabilities
11,813 11,363 12,030 12,273 16,688 15,450 15,608 14,897 15,605 17,392 19,201
Total Current Liabilities
2,430 3,587 5,654 5,260 4,866 3,681 4,274 3,803 4,933 6,399 5,439
Short-Term Debt
3.00 64 1,801 2,253 1,416 13 261 20 531 1,778 299
Accounts Payable
209 447 530 349 542 513 794 862 942 960 1,144
Accrued Expenses
1,970 2,312 2,456 2,246 2,109 2,197 2,436 2,160 2,646 2,773 3,201
Other Current Liabilities
248 764 867 412 800 958 783 761 814 887 795
Total Noncurrent Liabilities
9,383 7,776 6,376 7,013 11,822 11,769 11,334 11,094 10,672 10,993 13,762
Long-Term Debt
5,674 5,420 3,815 4,803 8,592 9,130 8,804 8,915 8,571 8,968 11,137
Noncurrent Deferred & Payable Income Tax Liabilities
735 18 191 328 595 330 310 144 134 155 220
Other Noncurrent Operating Liabilities
2,974 2,338 2,370 1,882 2,635 2,309 2,220 2,035 1,967 1,870 2,405
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
6,320 6,733 7,012 8,726 13,877 15,326 16,622 17,573 19,530 22,003 24,472
Total Preferred & Common Equity
6,320 6,733 7,011 8,726 13,877 15,337 16,623 17,573 19,282 21,770 24,233
Preferred Stock
0.00 0.00 0.00 0.00 0.00 10 0.00 0.00 0.00 0.00 0.00
Total Common Equity
6,320 6,733 7,011 8,726 13,877 15,327 16,623 17,574 19,281 21,770 24,232
Common Stock
16,876 17,030 17,177 17,362 17,577 19,749 20,003 20,306 20,664 21,073 21,522
Retained Earnings
-8,927 -8,581 -8,390 -6,953 -2,253 -2,378 -1,392 -750 819 2,673 5,571
Treasury Stock
-1,717 -1,717 -1,717 -1,717 -1,717 -2,251 -2,251 -2,251 -2,251 -2,251 -2,251
Accumulated Other Comprehensive Income / (Loss)
88 1.00 -59 33 270 207 263 269 49 275 -610
Noncontrolling Interest
- - - - - - - 0.00 248 233 239

Quarterly Balance Sheets for Boston Scientific

This table presents Boston Scientific's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
35,136 36,669 37,108 38,078 39,395 40,140 41,559 42,707 44,351 45,216 45,461
Total Current Assets
6,514 8,185 8,991 8,761 6,920 7,335 7,121 8,035 8,684 7,972 8,164
Cash & Equivalents
865 2,329 2,913 2,502 414 725 534 1,275 1,453 539 609
Note & Lease Receivable
2,228 2,304 2,400 2,501 2,558 2,693 2,815 2,828 3,027 3,049 3,113
Inventories, net
2,484 2,561 2,608 2,753 2,810 2,867 2,861 2,921 3,117 3,235 3,317
Prepaid Expenses
621 671 756 674 831 756 613 701 729 760 745
Current Deferred & Refundable Income Taxes
315 319 315 332 307 294 298 310 358 390 381
Plant, Property, & Equipment, net
2,859 2,897 2,951 3,072 3,294 3,389 3,461 3,795 4,063 4,126 4,183
Total Noncurrent Assets
25,762 25,588 25,166 26,245 29,182 29,416 30,978 30,877 31,603 33,117 33,114
Long-Term Investments
- - - - - - - - - 2,245 2,292
Goodwill
14,387 14,361 14,397 15,033 17,089 17,340 18,076 18,214 18,536 18,640 18,736
Intangible Assets
6,003 5,839 5,417 5,754 6,684 6,566 7,260 7,162 7,060 6,918 6,860
Noncurrent Deferred & Refundable Income Taxes
3,841 3,792 3,801 3,816 3,655 3,676 3,778 3,669 3,953 3,909 3,840
Other Noncurrent Operating Assets
1,531 1,596 1,551 1,642 1,754 1,834 1,864 1,832 2,054 1,405 1,386
Total Liabilities & Shareholders' Equity
35,136 36,669 37,108 38,078 39,395 40,140 41,559 42,707 44,351 45,216 45,461
Total Liabilities
15,605 16,501 16,499 17,122 17,392 17,694 18,906 19,077 18,247 20,044 19,589
Total Current Liabilities
4,933 4,916 5,576 5,910 6,399 5,058 5,190 5,328 4,571 6,428 5,982
Short-Term Debt
531 1,085 1,580 1,652 1,778 777 480 483 41 1,709 1,044
Accounts Payable
942 921 906 907 960 1,004 962 1,002 1,141 1,231 1,250
Accrued Expenses
2,646 2,083 2,320 2,460 2,773 2,354 2,797 2,981 2,514 2,756 2,969
Other Current Liabilities
814 827 770 891 887 923 952 862 875 732 719
Total Noncurrent Liabilities
10,672 11,585 10,923 11,212 10,993 12,636 13,716 13,749 13,676 13,616 13,607
Long-Term Debt
8,571 9,534 8,991 9,233 8,968 10,532 11,107 11,117 10,988 10,915 10,909
Noncurrent Deferred & Payable Income Tax Liabilities
134 132 132 138 155 158 226 242 219 221 264
Other Noncurrent Operating Liabilities
1,967 1,919 1,800 1,841 1,870 1,946 2,383 2,390 2,469 2,480 2,434
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
19,530 20,168 20,609 20,956 22,003 22,446 22,653 23,630 26,104 25,172 25,873
Total Preferred & Common Equity
19,282 19,926 20,371 20,708 21,770 22,212 22,418 23,394 25,864 24,930 25,630
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
19,281 19,925 20,372 20,708 21,770 22,212 22,418 23,395 25,864 24,930 25,630
Common Stock
20,664 20,730 20,820 20,980 21,073 21,144 21,247 21,436 21,601 21,734 21,899
Retained Earnings
819 1,314 1,639 2,107 2,673 3,347 4,144 4,899 6,912 7,818 8,400
Treasury Stock
-2,251 -2,251 -2,251 -2,251 -2,251 -2,251 -2,251 -2,251 -2,251 -4,318 -4,318
Accumulated Other Comprehensive Income / (Loss)
49 132 164 -128 275 -28 -722 -689 -398 -304 -351
Noncontrolling Interest
248 242 238 248 233 233 235 236 240 242 243

Annual Metrics And Ratios for Boston Scientific

This table displays calculated financial ratios and metrics derived from Boston Scientific's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
1.31% 12.16% 7.89% 8.57% 9.28% -7.66% 19.92% 6.68% 12.29% 17.61% 19.87%
EBITDA Growth
-0.45% 184.05% 61.59% 27.15% -13.47% -34.01% 73.89% 9.24% 24.22% 13.64% 33.96%
EBIT Growth
-24.91% 212.02% 183.17% 43.15% -30.20% -75.69% 402.48% 13.69% 39.66% 15.69% 44.34%
NOPAT Growth
5.98% 542.36% -83.50% 1,123.75% 486.83% -100.54% 2,169.44% -12.95% 86.28% 12.06% 46.59%
Net Income Growth
-100.84% 245.19% -70.03% 1,506.73% 181.27% -101.74% 1,369.51% -32.95% 128.08% 15.95% 56.66%
EPS Growth
-100.00% 238.89% -68.00% 1,387.50% 179.83% -102.40% 962.50% -34.78% 137.78% 16.82% 55.20%
Operating Cash Flow Growth
-45.55% 71.06% 20.64% -78.26% 492.26% -17.86% 24.01% -18.40% 64.02% 37.24% 31.99%
Free Cash Flow Firm Growth
-842.56% 130.27% -151.45% -419.81% 265.05% -14.70% -149.81% 19.09% 62.08% -703.36% 160.15%
Invested Capital Growth
15.46% 2.94% 3.49% 25.69% 51.36% -8.72% 9.99% 7.65% 8.55% 16.46% 4.96%
Revenue Q/Q Growth
1.23% 2.61% 2.47% 1.57% 3.30% -1.94% 3.65% 0.92% 3.51% 5.26% 3.74%
EBITDA Q/Q Growth
475.21% 135.73% 27.13% 18.45% 10.41% 72.32% -7.02% 9.41% 3.88% 5.32% 4.85%
EBIT Q/Q Growth
37.76% 3,253.85% 13.49% 4.79% -13.82% 422.22% -12.15% 18.72% 5.14% 4.50% 7.83%
NOPAT Q/Q Growth
48.45% 1,464.86% -87.68% 137.12% 479.16% -200.00% 18.33% -6.36% 32.88% 3.23% 4.66%
Net Income Q/Q Growth
39.65% 328.40% -87.66% 149.40% 331.19% -102.21% -9.87% 6.89% 29.64% 3.30% 3.84%
EPS Q/Q Growth
37.93% 316.67% -86.67% 147.92% 332.47% -103.07% -10.39% 7.14% 30.49% 3.31% 3.74%
Operating Cash Flow Q/Q Growth
-2.81% 27.65% 0.56% -68.21% 57.87% -32.56% 37.91% 27.49% 6.37% 17.00% -1.99%
Free Cash Flow Firm Q/Q Growth
-10.39% 74.86% -27.18% -51.62% 162.43% 179.94% -485.62% 33.05% -236.90% -994.32% 189.02%
Invested Capital Q/Q Growth
-2.02% 3.01% -4.75% 6.03% 16.52% -5.58% 0.69% -1.18% 2.55% 10.21% -0.04%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
70.94% 71.09% 71.34% 71.37% 70.98% 65.05% 68.78% 68.81% 69.49% 68.61% 69.01%
EBITDA Margin
5.87% 14.87% 22.27% 26.08% 20.65% 14.76% 21.40% 21.91% 24.24% 23.43% 26.07%
Operating Margin
-3.78% 5.33% 14.20% 15.33% 14.14% -0.81% 10.09% 13.00% 16.45% 15.54% 18.00%
EBIT Margin
-4.90% 4.89% 12.83% 16.92% 10.81% 2.84% 11.92% 12.70% 15.80% 15.54% 18.60%
Profit (Net Income) Margin
-3.20% 4.14% 1.15% 17.01% 43.78% -0.83% 8.76% 5.50% 11.18% 11.02% 14.41%
Tax Burden Percent
36.77% 196.05% 11.15% 117.51% 684.13% 103.80% 96.75% 61.17% 80.20% 80.89% 85.44%
Interest Burden Percent
177.60% 43.17% 80.36% 85.56% 59.22% -28.01% 75.94% 70.83% 88.22% 87.67% 90.65%
Effective Tax Rate
0.00% -96.05% 88.75% -17.51% -584.13% 0.00% 3.35% 38.83% 19.80% 19.11% 14.56%
Return on Invested Capital (ROIC)
-1.82% 7.40% 1.18% 12.61% 52.85% -0.25% 5.11% 4.09% 7.05% 7.01% 9.31%
ROIC Less NNEP Spread (ROIC-NNEP)
-2.73% -2.55% 0.42% 11.01% -15.24% -0.57% 3.35% -0.01% 3.51% 4.21% 7.35%
Return on Net Nonoperating Assets (RNNOA)
-1.92% -2.08% 0.33% 8.63% -11.26% -0.31% 1.41% -0.01% 1.54% 1.88% 3.13%
Return on Equity (ROE)
-3.74% 5.32% 1.51% 21.24% 41.59% -0.56% 6.52% 4.08% 8.58% 8.89% 12.45%
Cash Return on Invested Capital (CROIC)
-16.17% 4.50% -2.24% -10.16% 11.98% 8.87% -4.41% -3.28% -1.15% -8.20% 4.47%
Operating Return on Assets (OROA)
-2.08% 2.26% 6.25% 8.30% 4.50% 0.92% 4.50% 4.98% 6.66% 6.99% 8.99%
Return on Assets (ROA)
-1.36% 1.92% 0.56% 8.35% 18.23% -0.27% 3.30% 2.16% 4.71% 4.95% 6.96%
Return on Common Equity (ROCE)
-3.74% 5.32% 1.51% 21.23% 41.59% -0.56% 6.52% 4.08% 8.52% 8.79% 12.32%
Return on Equity Simple (ROE_SIMPLE)
-3.78% 5.15% 1.48% 19.15% 33.87% -0.53% 6.26% 3.97% 8.26% 8.48% 0.00%
Net Operating Profit after Tax (NOPAT)
-198 876 145 1,770 10,385 -56 1,159 1,009 1,879 2,106 3,087
NOPAT Margin
-2.65% 10.45% 1.60% 18.02% 96.74% -0.56% 9.75% 7.95% 13.20% 12.57% 15.38%
Net Nonoperating Expense Percent (NNEP)
0.91% 9.94% 0.76% 1.60% 68.09% 0.32% 1.76% 4.10% 3.54% 2.80% 1.97%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - 3.81% 6.56% 6.43% 8.60%
Cost of Revenue to Revenue
29.06% 28.91% 28.66% 28.64% 29.03% 34.95% 31.22% 31.19% 30.51% 31.39% 30.99%
SG&A Expenses to Revenue
38.42% 36.95% 36.41% 36.33% 36.71% 38.20% 36.67% 35.64% 36.45% 35.73% 34.31%
R&D to Revenue
11.72% 10.97% 11.02% 11.33% 10.94% 11.53% 10.13% 10.43% 9.93% 9.64% 10.22%
Operating Expenses to Revenue
74.72% 65.76% 57.14% 56.03% 56.84% 65.85% 58.70% 55.82% 53.03% 53.07% 51.02%
Earnings before Interest and Taxes (EBIT)
-366 410 1,161 1,662 1,160 282 1,417 1,611 2,250 2,603 3,734
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
439 1,247 2,015 2,562 2,217 1,463 2,544 2,779 3,452 3,923 5,234
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
3.92 4.37 4.86 5.60 4.54 3.36 3.64 3.77 4.39 6.05 5.83
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
3.32 3.51 3.76 4.98 5.87 5.19 5.09 5.23 5.95 7.86 7.04
Price to Earnings (P/E)
0.00 84.88 327.32 29.27 13.41 0.00 61.46 103.23 53.94 71.04 48.78
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 1.18% 0.31% 3.42% 7.46% 0.00% 1.63% 0.97% 1.85% 1.41% 2.05%
Enterprise Value to Invested Capital (EV/IC)
2.58 2.89 3.17 3.57 3.08 2.73 2.85 2.90 3.36 4.40 4.45
Enterprise Value to Revenue (EV/Rev)
4.03 4.14 4.36 5.68 6.78 5.94 5.69 5.86 6.54 8.49 7.53
Enterprise Value to EBITDA (EV/EBITDA)
68.71 27.86 19.59 21.79 32.85 40.26 26.60 26.73 26.99 36.25 28.86
Enterprise Value to EBIT (EV/EBIT)
0.00 84.73 34.00 33.58 62.78 208.85 47.76 46.11 41.41 54.63 40.46
Enterprise Value to NOPAT (EV/NOPAT)
0.00 39.64 272.93 31.54 7.01 0.00 58.40 73.63 49.58 67.54 48.94
Enterprise Value to Operating Cash Flow (EV/OCF)
43.65 29.39 27.68 180.04 39.66 39.06 36.19 48.68 37.23 41.40 33.32
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 65.14 0.00 0.00 30.93 29.33 0.00 0.00 0.00 0.00 101.88
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.90 0.81 0.80 0.81 0.72 0.60 0.55 0.51 0.47 0.49 0.47
Long-Term Debt to Equity
0.90 0.81 0.54 0.55 0.62 0.60 0.53 0.51 0.44 0.41 0.46
Financial Leverage
0.71 0.82 0.78 0.78 0.74 0.55 0.42 0.44 0.44 0.45 0.43
Leverage Ratio
2.75 2.78 2.70 2.54 2.28 2.10 1.97 1.89 1.82 1.79 1.79
Compound Leverage Factor
4.89 1.20 2.17 2.18 1.35 -0.59 1.50 1.34 1.61 1.57 1.62
Debt to Total Capital
47.32% 44.89% 44.47% 44.71% 41.90% 37.37% 35.29% 33.71% 31.79% 32.81% 31.85%
Short-Term Debt to Total Capital
0.03% 0.52% 14.26% 14.28% 5.93% 0.05% 1.02% 0.08% 1.85% 5.43% 0.83%
Long-Term Debt to Total Capital
47.30% 44.36% 30.21% 30.43% 35.97% 37.31% 34.27% 33.63% 29.94% 27.38% 31.02%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.04% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.87% 0.71% 0.67%
Common Equity to Total Capital
52.68% 55.11% 55.52% 55.29% 58.10% 62.64% 64.71% 66.30% 67.34% 66.48% 67.48%
Debt to EBITDA
12.93 4.40 2.79 2.75 4.51 6.25 3.56 3.22 2.64 2.74 2.18
Net Debt to EBITDA
12.21 4.24 2.69 2.70 4.42 5.06 2.81 2.88 2.39 2.63 1.81
Long-Term Debt to EBITDA
12.92 4.35 1.89 1.87 3.88 6.24 3.46 3.21 2.48 2.29 2.13
Debt to NOPAT
-28.66 6.26 38.83 3.99 0.96 -163.27 7.82 8.86 4.84 5.10 3.70
Net Debt to NOPAT
-27.05 6.03 37.53 3.90 0.94 -132.30 6.16 7.94 4.38 4.91 3.07
Long-Term Debt to NOPAT
-28.64 6.18 26.38 2.71 0.83 -163.04 7.60 8.84 4.56 4.26 3.61
Altman Z-Score
0.99 1.41 1.64 2.58 2.63 2.36 2.86 3.26 3.96 5.30 5.43
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.01% 0.01% 0.00% 0.00% -0.01% -0.01% 0.67% 1.16% 1.02%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.43 0.90 0.68 0.76 0.97 1.82 1.48 1.51 1.32 1.08 1.62
Quick Ratio
0.66 0.47 0.31 0.33 0.42 0.89 0.87 0.76 0.63 0.46 0.90
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-1,762 533 -274 -1,426 2,354 2,008 -1,000 -809 -307 -2,465 1,483
Operating Cash Flow to CapEx
279.76% 340.63% 447.02% 102.65% 404.41% 414.29% 346.30% 264.93% 354.03% 436.47% 517.58%
Free Cash Flow to Firm to Interest Expense
-6.20 2.29 -1.20 -5.92 4.98 5.56 -2.93 -1.72 -1.16 -8.08 4.25
Operating Cash Flow to Interest Expense
2.43 5.07 6.23 1.29 3.88 4.18 5.48 3.25 9.45 11.26 12.99
Operating Cash Flow Less CapEx to Interest Expense
1.56 3.58 4.83 0.03 2.92 3.17 3.90 2.02 6.78 8.68 10.48
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.43 0.46 0.49 0.49 0.42 0.32 0.38 0.39 0.42 0.45 0.48
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
2.22 2.46 2.55 2.51 2.27 2.37 2.51 2.28 2.00 1.99 2.16
Fixed Asset Turnover
4.99 5.38 5.44 5.65 5.56 4.76 5.48 5.40 5.37 5.44 5.48
Accounts Payable Turnover
9.23 7.39 5.31 6.40 6.99 6.57 5.68 4.78 4.82 5.53 5.91
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
164.78 148.39 143.09 145.58 160.77 154.32 145.62 160.40 182.75 183.78 168.77
Days Payable Outstanding (DPO)
39.56 49.39 68.76 57.03 52.18 55.57 64.28 76.40 75.77 66.03 61.72
Cash Conversion Cycle (CCC)
125.22 99.00 74.32 88.56 108.59 98.76 81.34 84.01 106.98 117.76 107.05
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
11,678 12,021 12,440 15,636 23,667 21,603 23,762 25,580 27,766 32,337 33,941
Invested Capital Turnover
0.69 0.71 0.74 0.70 0.55 0.44 0.52 0.51 0.53 0.56 0.61
Increase / (Decrease) in Invested Capital
1,564 343 419 3,196 8,031 -2,064 2,159 1,818 2,186 4,571 1,604
Enterprise Value (EV)
30,163 34,741 39,470 55,814 72,820 58,897 67,674 74,280 93,176 142,207 151,061
Market Capitalization
24,805 29,453 34,042 48,904 63,029 51,478 60,534 66,273 84,691 131,642 141,351
Book Value per Share
$4.70 $4.94 $5.11 $6.31 $9.96 $10.70 $11.67 $12.27 $13.16 $14.77 $16.35
Tangible Book Value per Share
($4.72) ($4.28) ($4.24) ($4.02) ($3.00) ($0.38) ($1.04) ($0.87) ($0.76) ($1.36) ($0.72)
Total Capital
11,997 12,217 12,628 15,782 23,885 24,469 25,687 26,508 28,632 32,749 35,908
Total Debt
5,677 5,484 5,616 7,056 10,008 9,143 9,065 8,935 9,102 10,746 11,436
Total Long-Term Debt
5,674 5,420 3,815 4,803 8,592 9,130 8,804 8,915 8,571 8,968 11,137
Net Debt
5,358 5,288 5,428 6,910 9,791 7,409 7,140 8,007 8,237 10,332 9,471
Capital Expenditures (CapEx)
247 347 319 302 454 364 540 576 707 787 876
Debt-free, Cash-free Net Working Capital (DFCFNWC)
725 -480 -219 850 1,032 1,292 379 1,049 1,247 1,885 1,689
Debt-free Net Working Capital (DFNWC)
1,044 -284 -31 996 1,249 3,026 2,304 1,977 2,112 2,299 3,654
Net Working Capital (NWC)
1,041 -348 -1,832 -1,257 -167 3,013 2,043 1,957 1,581 521 3,355
Net Nonoperating Expense (NNE)
41 529 41 99 5,685 26 118 311 287 260 195
Net Nonoperating Obligations (NNO)
5,358 5,288 5,428 6,910 9,790 6,277 7,140 8,007 8,236 10,334 9,469
Total Depreciation and Amortization (D&A)
805 837 854 900 1,057 1,181 1,127 1,168 1,202 1,320 1,500
Debt-free, Cash-free Net Working Capital to Revenue
9.70% -5.72% -2.42% 8.65% 9.61% 13.03% 3.19% 8.27% 8.76% 11.26% 8.41%
Debt-free Net Working Capital to Revenue
13.96% -3.39% -0.34% 10.14% 11.63% 30.53% 19.38% 15.59% 14.83% 13.73% 18.20%
Net Working Capital to Revenue
13.92% -4.15% -20.25% -12.80% -1.56% 30.39% 17.19% 15.43% 11.10% 3.11% 16.71%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.18) $0.26 $0.08 $1.21 $3.38 ($0.08) $0.69 $0.45 $1.08 $1.26 $1.96
Adjusted Weighted Average Basic Shares Outstanding
1.34B 1.36B 1.37B 1.38B 1.39B 1.42B 1.42B 1.43B 1.45B 1.47B 1.48B
Adjusted Diluted Earnings per Share
($0.18) $0.25 $0.08 $1.19 $3.33 ($0.08) $0.69 $0.45 $1.07 $1.25 $1.94
Adjusted Weighted Average Diluted Shares Outstanding
1.34B 1.38B 1.39B 1.40B 1.41B 1.42B 1.43B 1.44B 1.46B 1.49B 1.49B
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $3.38 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
1.35B 1.36B 1.37B 1.39B 1.40B 1.42B 1.43B 1.43B 1.47B 1.48B 1.48B
Normalized Net Operating Profit after Tax (NOPAT)
693 923 1,072 1,161 1,219 478 1,839 1,231 1,938 2,427 3,394
Normalized NOPAT Margin
9.27% 11.01% 11.84% 11.82% 11.35% 4.82% 15.47% 9.71% 13.61% 14.49% 16.91%
Pre Tax Income Margin
-8.69% 2.11% 10.31% 14.48% 6.40% -0.80% 9.05% 9.00% 13.94% 13.63% 16.86%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-1.29 1.76 5.07 6.90 2.45 0.78 4.16 3.43 8.49 8.53 10.70
NOPAT to Interest Expense
-0.70 3.76 0.63 7.34 21.96 -0.16 3.40 2.15 7.09 6.90 8.84
EBIT Less CapEx to Interest Expense
-2.16 0.27 3.68 5.64 1.49 -0.23 2.57 2.20 5.82 5.95 8.19
NOPAT Less CapEx to Interest Expense
-1.57 2.27 -0.76 6.09 21.00 -1.16 1.81 0.92 4.42 4.32 6.33
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% -34.15% 5.28% 7.88% 1.76% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% -686.59% 5.28% 7.88% 1.76% 0.00% 0.00%

Quarterly Metrics And Ratios for Boston Scientific

This table displays calculated financial ratios and metrics derived from Boston Scientific's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - - - - - 1,483,885,456.00 1,486,355,179.00 1,449,229,526.00
DEI Adjusted Shares Outstanding
- - - - - - - - 1,483,885,456.00 1,486,355,179.00 1,449,229,526.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - 0.90 0.61 0.40
Growth Metrics
- - - - - - - - - - -
Revenue Growth
13.78% 14.48% 19.34% 22.47% 20.93% 22.84% 20.34% 15.85% 11.58% 7.53% 1.44%
EBITDA Growth
23.55% 1.76% 7.67% 21.63% 31.80% 73.89% 30.67% 8.92% 24.13% 7.76% -13.15%
EBIT Growth
33.01% 0.20% 10.67% 18.42% 31.02% 107.65% 37.22% 18.62% 41.15% 11.92% -18.83%
NOPAT Growth
40.65% 22.38% -10.43% 11.26% 40.47% 73.56% 64.20% 21.59% 64.89% 45.35% -22.35%
Net Income Growth
57.01% 19.26% -7.14% 11.71% 36.31% 146.89% 61.32% 19.01% 99.26% 13.84% -23.18%
EPS Growth
57.14% 22.22% -5.88% 11.76% 36.36% 140.91% 59.38% 18.42% 100.00% 15.09% -21.57%
Operating Cash Flow Growth
-13.68% 23.56% 43.55% 52.14% 229.88% 58.18% 34.03% -6.32% -35.67% 14.62% -21.97%
Free Cash Flow Firm Growth
-210.70% 9.76% -184.14% -144.68% -178.28% -526.68% -115.36% 79.21% 63.68% 93.67% 91.65%
Invested Capital Growth
7.21% 4.26% 8.37% 16.46% 16.07% 19.24% 15.73% 4.96% 8.02% 3.87% 2.86%
Revenue Q/Q Growth
3.52% 6.85% 2.16% 8.39% 2.21% 8.54% 0.08% 4.34% -1.55% 4.59% -5.59%
EBITDA Q/Q Growth
11.10% -17.64% 30.32% 1.99% 20.39% 8.66% -2.06% -15.70% 38.36% -5.67% -21.07%
EBIT Q/Q Growth
18.77% -26.59% 50.30% -9.64% 31.41% 16.35% -0.68% -22.93% 58.48% -7.75% -27.97%
NOPAT Q/Q Growth
-6.09% -27.16% 28.90% 26.19% 18.56% -10.00% 21.94% -6.55% 60.79% -20.67% -34.86%
Net Income Q/Q Growth
-2.18% -34.69% 45.34% 20.30% 19.36% 18.30% -5.03% -11.26% 99.85% -32.41% -35.91%
EPS Q/Q Growth
-2.94% -33.33% 45.45% 18.75% 18.42% 17.78% -3.77% -11.76% 100.00% -32.22% -34.43%
Operating Cash Flow Q/Q Growth
-82.86% 395.73% 23.25% 45.31% -62.84% 137.71% 4.43% 1.56% -74.49% 323.56% -28.90%
Free Cash Flow Firm Q/Q Growth
14.75% 44.59% -131.22% -124.00% 3.04% -24.79% 20.54% 78.37% -69.37% 78.26% -4.85%
Invested Capital Q/Q Growth
2.49% -0.67% 3.79% 10.21% 2.14% 2.05% 0.74% -0.04% 5.12% -1.87% -0.25%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
68.67% 69.17% 68.83% 67.84% 68.84% 67.65% 69.93% 69.59% 69.46% 70.71% 66.72%
EBITDA Margin
25.44% 19.61% 25.02% 23.54% 27.73% 27.76% 27.17% 21.95% 30.85% 27.82% 23.26%
Operating Margin
17.51% 12.62% 17.42% 14.80% 19.75% 16.18% 20.69% 15.61% 21.16% 21.65% 16.12%
EBIT Margin
17.56% 12.06% 17.75% 14.80% 19.02% 20.39% 20.24% 14.95% 24.06% 21.22% 16.19%
Profit (Net Income) Margin
12.79% 7.82% 11.12% 12.34% 14.41% 15.71% 14.91% 12.68% 25.74% 16.63% 11.29%
Tax Burden Percent
81.09% 76.67% 69.96% 96.24% 83.48% 84.48% 80.40% 95.71% 115.23% 85.38% 79.13%
Interest Burden Percent
89.81% 84.51% 89.56% 86.67% 90.76% 91.18% 91.61% 88.61% 92.81% 91.77% 88.10%
Effective Tax Rate
18.91% 23.33% 29.90% 3.93% 16.52% 15.52% 19.49% 4.43% -15.15% 14.62% 20.87%
Return on Invested Capital (ROIC)
7.59% 5.32% 6.89% 7.92% 9.41% 8.16% 10.19% 9.04% 14.62% 11.29% 7.80%
ROIC Less NNEP Spread (ROIC-NNEP)
6.94% 4.38% 6.32% 7.00% 8.39% 9.26% 9.24% 7.84% 15.33% 10.33% 7.02%
Return on Net Nonoperating Assets (RNNOA)
3.03% 1.82% 2.58% 3.13% 3.72% 4.01% 3.88% 3.34% 6.36% 4.51% 2.75%
Return on Equity (ROE)
10.62% 7.15% 9.46% 11.05% 13.13% 12.17% 14.06% 12.38% 20.98% 15.81% 10.55%
Cash Return on Invested Capital (CROIC)
0.43% 3.42% -0.80% -8.20% -7.30% -9.09% -5.26% 4.47% 2.79% 7.68% 8.09%
Operating Return on Assets (OROA)
7.42% 5.20% 7.83% 6.65% 8.69% 9.59% 9.70% 7.22% 11.74% 10.27% 7.74%
Return on Assets (ROA)
5.41% 3.37% 4.91% 5.55% 6.59% 7.39% 7.14% 6.13% 12.56% 8.05% 5.39%
Return on Common Equity (ROCE)
10.48% 7.06% 9.35% 10.92% 12.98% 12.03% 13.91% 12.25% 20.78% 15.65% 10.45%
Return on Equity Simple (ROE_SIMPLE)
8.89% 8.95% 8.63% 0.00% 9.12% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
547 399 514 648 769 692 844 788 1,268 1,006 655
NOPAT Margin
14.19% 9.68% 12.21% 14.21% 16.49% 13.67% 16.66% 14.92% 24.37% 18.48% 12.75%
Net Nonoperating Expense Percent (NNEP)
0.65% 0.94% 0.56% 0.92% 1.03% -1.10% 0.95% 1.20% -0.71% 0.96% 0.78%
Return On Investment Capital (ROIC_SIMPLE)
- - - 1.98% 2.28% 2.02% 2.40% 2.20% 3.41% 2.66% 1.73%
Cost of Revenue to Revenue
31.35% 30.83% 31.17% 32.14% 31.16% 32.35% 30.07% 30.43% 30.56% 29.29% 33.28%
SG&A Expenses to Revenue
35.37% 35.10% 37.11% 35.34% 34.25% 33.91% 34.37% 34.68% 34.23% 33.13% 32.76%
R&D to Revenue
9.49% 9.30% 9.67% 10.06% 9.50% 10.39% 10.15% 10.77% 9.92% 10.18% 10.12%
Operating Expenses to Revenue
51.17% 56.55% 51.41% 53.05% 49.07% 51.47% 49.24% 54.00% 48.30% 49.06% 50.60%
Earnings before Interest and Taxes (EBIT)
677 497 747 675 887 1,032 1,025 790 1,252 1,155 832
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
981 808 1,053 1,074 1,293 1,405 1,376 1,160 1,605 1,514 1,195
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 5.56 5.96 6.05 6.70 7.09 6.18 5.83 3.60 2.54 2.47
Price to Tangible Book Value (P/TBV)
0.00 202.90 0.00 0.00 0.00 0.00 0.00 0.00 347.44 0.00 1,860.56
Price to Revenue (P/Rev)
0.00 7.43 7.76 7.86 8.48 8.59 7.48 7.04 4.52 3.02 3.00
Price to Earnings (P/E)
0.00 61.94 68.87 71.04 73.27 63.44 51.83 48.78 26.12 17.26 18.06
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 1.61% 1.45% 1.41% 1.36% 1.58% 1.93% 2.05% 3.83% 5.79% 5.54%
Enterprise Value to Invested Capital (EV/IC)
0.00 4.28 4.50 4.40 4.83 5.05 4.57 4.45 2.88 2.10 2.08
Enterprise Value to Revenue (EV/Rev)
0.00 7.95 8.30 8.49 9.10 9.20 8.02 7.53 4.99 3.50 3.44
Enterprise Value to EBITDA (EV/EBITDA)
0.00 33.18 35.45 36.25 37.39 36.74 31.09 28.86 18.56 13.00 13.25
Enterprise Value to EBIT (EV/EBIT)
0.00 50.07 53.01 54.63 56.05 54.06 44.82 40.46 25.11 17.41 18.01
Enterprise Value to NOPAT (EV/NOPAT)
0.00 57.56 64.73 67.54 68.62 64.93 52.63 48.94 28.54 18.64 19.31
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 46.02 44.97 41.40 41.89 39.72 33.55 33.32 23.71 16.23 17.14
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 127.75 0.00 0.00 0.00 0.00 0.00 101.88 107.50 27.86 26.04
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.53 0.51 0.52 0.49 0.50 0.51 0.49 0.47 0.42 0.50 0.46
Long-Term Debt to Equity
0.47 0.44 0.44 0.41 0.47 0.49 0.47 0.46 0.42 0.43 0.42
Financial Leverage
0.44 0.42 0.41 0.45 0.44 0.43 0.42 0.43 0.42 0.44 0.39
Leverage Ratio
1.82 1.81 1.80 1.79 1.80 1.82 1.81 1.79 1.74 1.81 1.78
Compound Leverage Factor
1.63 1.53 1.61 1.56 1.64 1.66 1.66 1.58 1.62 1.67 1.57
Debt to Total Capital
34.49% 33.90% 34.19% 32.81% 33.50% 33.84% 32.93% 31.85% 29.70% 33.40% 31.60%
Short-Term Debt to Total Capital
3.52% 5.07% 5.19% 5.43% 2.30% 1.40% 1.37% 0.83% 0.11% 4.52% 2.76%
Long-Term Debt to Total Capital
30.97% 28.84% 29.00% 27.38% 31.20% 32.44% 31.56% 31.02% 29.59% 28.88% 28.84%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.79% 0.76% 0.78% 0.71% 0.69% 0.69% 0.67% 0.67% 0.65% 0.64% 0.64%
Common Equity to Total Capital
64.72% 65.34% 65.04% 66.48% 65.80% 65.47% 66.41% 67.48% 69.65% 65.96% 67.76%
Debt to EBITDA
2.92 2.90 2.92 2.74 2.65 2.50 2.32 2.18 1.99 2.23 2.18
Net Debt to EBITDA
2.28 2.10 2.25 2.63 2.48 2.39 2.07 1.81 1.73 1.74 1.65
Long-Term Debt to EBITDA
2.62 2.46 2.48 2.29 2.47 2.40 2.23 2.13 1.98 1.93 1.99
Debt to NOPAT
5.22 5.02 5.34 5.10 4.86 4.42 3.93 3.70 3.06 3.20 3.18
Net Debt to NOPAT
4.08 3.64 4.11 4.91 4.55 4.22 3.50 3.07 2.66 2.49 2.41
Long-Term Debt to NOPAT
4.69 4.27 4.53 4.26 4.53 4.24 3.77 3.61 3.05 2.77 2.90
Altman Z-Score
0.00 4.74 4.97 5.13 5.74 5.77 5.32 5.21 3.95 2.73 2.78
Noncontrolling Interest Sharing Ratio
1.31% 1.27% 1.23% 1.16% 1.12% 1.09% 1.08% 1.02% 0.98% 1.00% 0.97%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.67 1.61 1.48 1.08 1.45 1.37 1.51 1.62 1.90 1.24 1.36
Quick Ratio
0.94 0.95 0.85 0.46 0.68 0.65 0.77 0.90 0.98 0.56 0.62
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-1,367 -757 -1,751 -3,923 -3,803 -4,746 -3,771 -816 -1,381 -300 -315
Operating Cash Flow to CapEx
92.13% 524.52% 559.78% 529.45% 289.30% 819.11% 741.99% 388.60% 196.61% 755.90% 582.22%
Free Cash Flow to Firm to Interest Expense
-19.81 -9.84 -22.17 -49.03 -46.38 -52.73 -43.35 -9.06 -15.35 -3.13 -3.15
Operating Cash Flow to Interest Expense
2.38 10.56 12.68 18.20 6.60 14.29 15.44 15.16 3.87 15.35 10.48
Operating Cash Flow Less CapEx to Interest Expense
-0.20 8.55 10.42 14.76 4.32 12.54 13.36 11.26 1.90 13.32 8.68
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.42 0.43 0.44 0.45 0.46 0.47 0.48 0.48 0.49 0.48 0.48
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
1.96 1.95 1.91 1.99 2.03 2.15 2.14 2.16 2.13 2.07 2.08
Fixed Asset Turnover
5.47 5.55 5.58 5.44 5.59 5.77 5.64 5.48 5.53 5.53 5.28
Accounts Payable Turnover
5.05 5.24 5.38 5.53 5.72 6.28 6.37 5.91 5.93 5.76 5.77
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
186.42 187.60 190.63 183.78 180.08 170.09 170.34 168.77 171.76 176.17 175.09
Days Payable Outstanding (DPO)
72.33 69.70 67.87 66.03 63.86 58.10 57.31 61.72 61.57 63.38 63.21
Cash Conversion Cycle (CCC)
114.09 117.90 122.76 117.76 116.21 111.99 113.03 107.05 110.19 112.79 111.88
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
28,458 28,268 29,340 32,337 33,030 33,706 33,955 33,941 35,679 35,012 34,925
Invested Capital Turnover
0.53 0.55 0.56 0.56 0.57 0.60 0.61 0.61 0.60 0.61 0.61
Increase / (Decrease) in Invested Capital
1,914 1,156 2,265 4,571 4,572 5,438 4,615 1,604 2,649 1,306 970
Enterprise Value (EV)
0.00 121,115 132,037 142,207 159,693 170,195 155,224 151,061 102,930 73,520 72,554
Market Capitalization
0.00 113,219 123,406 131,642 148,876 158,907 144,663 141,351 93,114 63,438 63,259
Book Value per Share
$13.57 $13.86 $14.06 $14.77 $15.05 $15.15 $15.79 $16.35 $17.43 $16.77 $17.69
Tangible Book Value per Share
($0.19) $0.38 ($0.05) ($1.36) ($1.15) ($1.97) ($1.34) ($0.72) $0.18 ($0.42) $0.02
Total Capital
30,787 31,180 31,841 32,749 33,755 34,240 35,230 35,908 37,133 37,796 37,826
Total Debt
10,619 10,571 10,885 10,746 11,309 11,587 11,600 11,436 11,029 12,624 11,953
Total Long-Term Debt
9,534 8,991 9,233 8,968 10,532 11,107 11,117 11,137 10,988 10,915 10,909
Net Debt
8,290 7,658 8,383 10,332 10,584 11,053 10,325 9,471 9,576 9,840 9,052
Capital Expenditures (CapEx)
178 155 179 275 187 157 181 351 177 195 180
Debt-free, Cash-free Net Working Capital (DFCFNWC)
2,025 2,082 2,001 1,885 2,329 1,877 1,915 1,689 2,701 2,714 2,617
Debt-free Net Working Capital (DFNWC)
4,354 4,995 4,503 2,299 3,054 2,411 3,190 3,654 4,154 3,253 3,226
Net Working Capital (NWC)
3,269 3,415 2,851 521 2,277 1,931 2,707 3,355 4,113 1,544 2,182
Net Nonoperating Expense (NNE)
54 77 46 85 97 -103 89 118 -71 101 75
Net Nonoperating Obligations (NNO)
8,290 7,659 8,384 10,334 10,584 11,053 10,325 9,469 9,575 9,840 9,052
Total Depreciation and Amortization (D&A)
304 311 306 399 406 373 351 370 353 359 363
Debt-free, Cash-free Net Working Capital to Revenue
13.77% 13.67% 12.58% 11.26% 13.27% 10.15% 9.90% 8.41% 13.10% 12.93% 12.42%
Debt-free Net Working Capital to Revenue
29.61% 32.80% 28.30% 13.73% 17.40% 13.04% 16.48% 18.20% 20.15% 15.49% 15.31%
Net Working Capital to Revenue
22.23% 22.43% 17.92% 3.11% 12.97% 10.44% 13.99% 16.71% 19.95% 7.35% 10.36%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.34 $0.22 $0.32 $0.38 $0.46 $0.54 $0.51 $0.45 $0.90 $0.62 $0.40
Adjusted Weighted Average Basic Shares Outstanding
1.47B 1.47B 1.47B 1.47B 1.48B 1.48B 1.48B 1.48B 1.48B 1.47B 1.45B
Adjusted Diluted Earnings per Share
$0.33 $0.22 $0.32 $0.38 $0.45 $0.53 $0.51 $0.45 $0.90 $0.61 $0.40
Adjusted Weighted Average Diluted Shares Outstanding
1.48B 1.48B 1.49B 1.49B 1.49B 1.49B 1.50B 1.49B 1.50B 1.47B 1.45B
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
1.47B 1.47B 1.47B 1.48B 1.48B 1.48B 1.48B 1.48B 1.49B 1.45B 1.45B
Normalized Net Operating Profit after Tax (NOPAT)
564 613 503 651 781 797 846 996 752 1,064 775
Normalized NOPAT Margin
14.61% 14.87% 11.96% 14.28% 16.76% 15.74% 16.71% 18.84% 14.45% 19.55% 15.08%
Pre Tax Income Margin
15.77% 10.19% 15.89% 12.82% 17.26% 18.59% 18.54% 13.25% 22.33% 19.48% 14.27%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
9.81 6.45 9.46 8.44 10.82 11.47 11.78 8.78 13.91 12.03 8.32
NOPAT to Interest Expense
7.93 5.18 6.50 8.11 9.38 7.69 9.70 8.76 14.09 10.48 6.55
EBIT Less CapEx to Interest Expense
7.23 4.44 7.19 5.00 8.54 9.72 9.70 4.88 11.94 10.00 6.52
NOPAT Less CapEx to Interest Expense
5.35 3.16 4.24 4.67 7.10 5.94 7.62 4.86 12.12 8.45 4.75
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.79% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.79% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Boston Scientific’s latest results show continued revenue growth and stronger operating profitability, although cash liquidity weakened after substantial investment and financing activity. Q2 2026 revenue increased to $5.44 billion from $5.06 billion in Q2 2025, a 7.5% year-over-year gain. Gross profit rose 12.4% to $3.85 billion, lifting the gross margin to approximately 70.7% from 67.7%.

Operating income increased 43.8% year over year to $1.18 billion, with the operating margin expanding to 21.6% from 16.2%. Common-shareholder net income rose to $907 million from $797 million, while diluted earnings per share increased to $0.61 from $0.53. However, Q2 earnings were below Q1 2026, when common-shareholder net income was $1.34 billion and diluted EPS was $0.90.

  • Consistent top-line expansion: Quarterly revenue increased from $3.17 billion in Q3 2022 to $5.44 billion in Q2 2026. Q2 2026 revenue was also 7.5% above the restated Q2 2025 level.
  • Improving gross margins: Gross margin reached approximately 70.7% in Q2 2026, compared with roughly 67.7% in Q2 2025 and 66.4% in Q2 2024, indicating favorable product mix, pricing, or operating leverage.
  • Operating leverage is becoming more visible: Q2 2026 operating expenses increased approximately 6.3% year over year, slower than revenue growth. As a result, operating income grew nearly 44% and the operating margin improved substantially.
  • Strong operating cash generation: Cash flow from operations increased to $1.47 billion in Q2 2026 from $1.29 billion in Q2 2025. Operating cash flow has generally remained positive across the reported quarters, reaching $1.36 billion in Q4 2025 and $1.34 billion in Q3 2025.
  • Higher cash generation after capital spending: Approximate operating cash flow less property and equipment purchases was $1.28 billion in Q2 2026, up from approximately $1.13 billion in Q2 2025. This provides funding for acquisitions, research and development, and debt service.
  • Growing asset base and equity: Total assets increased to $45.2 billion at June 30, 2026, from $41.6 billion a year earlier. Total equity and noncontrolling interests rose to $25.2 billion from $22.7 billion over the same period, supported in part by higher retained earnings.
  • Acquisition-led growth remains important: Boston Scientific spent approximately $3.4 billion on acquisitions during the first half of 2026, compared with roughly $1.0 billion in the first half of 2025. These investments may support future growth, but their success will depend on integration and returns.
  • Reported results include restatements: Several 2024 and 2025 comparison periods are marked as restated in the supplied data. Investors should rely on the company’s latest filings when assessing year-over-year trends and should recognize that some historical figures may differ from previously reported results.
  • Cash reserves declined sharply: Cash and equivalents fell to $539 million at the end of Q2 2026 from $1.45 billion at the end of Q1 and $1.28 billion at the end of Q3 2025. The decline followed $1.96 billion of investing cash outflows and $410 million of financing cash outflows during the quarter.
  • Leverage and working-capital risks require monitoring: Total debt was approximately $12.2 billion at June 30, 2026, while inventory increased to $3.24 billion from $2.86 billion a year earlier. The current ratio fell to about 1.24 from approximately 1.37 in Q2 2025 and 1.90 in Q1 2026, leaving less short-term liquidity flexibility.

Overall, the statements point to a company with a strong multi-year growth profile, expanding margins, and robust operating cash flow. The main risks are the pace of acquisition spending, declining cash balances, rising debt exposure, and the need to convert higher inventory and acquired assets into future revenue and earnings.

11/20/26 01:08 PM ETAI Generated. May Contain Errors.

Boston Scientific Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Boston Scientific's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Boston Scientific's net income appears to be on an upward trend, with a most recent value of $2.89 billion in 2025, compared with -$239 million in 2015. The previous period was $1.85 billion in 2024. See where experts think Boston Scientific is headed by visiting Boston Scientific's forecast page.

Boston Scientific's total operating income in 2025 was $3.61 billion, based on the following breakdown:
  • Total Gross Profit: $13.85 billion
  • Total Operating Expenses: $10.24 billion

Over the last 10 years, Boston Scientific's total revenue changed from $7.48 billion in 2015 to $20.07 billion in 2025, a change of 168.5%.

In the past 11 quarters, Boston Scientific's cash and equivalents has ranged from $414 million in Q4 2024 to $2.91 billion in Q2 2024, and is currently $609 million as of their latest financial filing in Q3 2026.

Boston Scientific had total debt of $11.44 billion at the end of 2025, a 6.4% increase from 2024, and a 101.4% increase since 2015.

Over the last 10 years, Boston Scientific's book value per share changed from 4.70 in 2015 to 16.35 in 2025, a change of 247.9%.



Financial statements for NYSE:BSX last updated on 11/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners